180 Life Sciences (ATNF) said Thursday that the US Patent and Trademark Office has issued a notice of allowance for a patent application covering a new method to prevent post-operative cognitive dysfunction, or POCD.
The patent centers on preventing or reducing POCD by using an anti-human tumor necrosis factor alpha monoclonal antibody before and during surgery.
POCD is a complication affecting elderly surgical patients that leads to delirium, memory loss, and other cognitive impairments, the company said.
180 Life Sciences said a patent, if issued, would boost its biotechnology portfolio while it shifts focus toward online casino and entertainment ventures through its gaming platform.
Shares of 180 Life Sciences were up 11% in recent Thursday trading.
Price: 0.99, Change: +0.10, Percent Change: +11.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.